Receiving ravulizumab treatment prior to enrollment
Receipt of OCS therapy equivalent to a daily dose ≥ 7.5 mg of prednisone/prednisolone for ≥ 4 continuous weeks directly preceding enrollment
A participant of childbearing potential must have a negative highly sensitive pregnancy test (serum or urine, as required by local regulations) taken at Screening before OCS tapering begins.
Willing to sign informed consent
You may not be if
Concurrent participation in an interventional clinical trial.
History of chronic hypoadrenalism (ie, Addison's disease).
Use of concomitant OCS for comorbid conditions other than gMG
Receipt of a biologic for gMG (e.g., efgartigimod, rozanolixizumab, inebilizumab, rituximab, intravenous immunoglobulin) within 5 half-lives of enrollment
Pregnant, breastfeeding, or intending to conceive during the course of the study
Clareo Health | A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab
